SAT-091 Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms

Background: Ruxolitinib is a JAK1/2 inhibitor that is FDA approved to treat certain myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). The JAK family kinases are targeted in cancers due to their role in cytokine receptor signal transduction, and are also ke...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Sapre, Manali, Tremblay, Douglas, Leiter, Amanda, Coltoff, Alexander, Geevarghese, Anita, Mascarhenas, John, Gallagher, Emily
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Adipose Tissue, Appetite, and Obesity
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552330/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-091
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados